Laura A. T. Cleghorn

This paper identifies thienothiazolocarboxamides as rapidly cidal antituberculosis agents that cause thiol collapse in Mycobacterium tuberculosis through EthA-mediated activation.

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

The paper identifies and evaluates dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis, showing activity across multiple media and differential sensitivity in resistant strains.

The paper describes the development of lysyl tRNA synthetase inhibitors for tuberculosis treatment, optimizing compounds for preclinical and potential clinical use.

This study identifies common biological features of MmpL3 inhibitors, showing potent activity against M. tuberculosis and highlighting their potential as drug candidates.